In a study reported in the August issue of the European Journal of Cancer, a group of American investigators reported findings from patients with melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) who survived longer than two years after treatment with PD-1 and PD-L1 inhibitors (immune checkpoint inhibitors).

In conclusion, most patients who survive more than 24 months after treatment with immune checkpoint inhibitors had durable benefit and favourable HRQoL outcomes. Chronic immune-related adverse events may be more common than previously thought. However, there were no long-term adverse cardiometabolic events (a combination of high blood pressure, high glucose levels, high levels of fats in the blood, and accumulation of fat in the tummy).

Read more in the European Journal of Cancer here